Faeth Therapeutics, Inc. (FTH) - Total Liabilities
Based on the latest financial reports, Faeth Therapeutics, Inc. (FTH) has total liabilities worth $16.35 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of Faeth Therapeutics, Inc. to measure how many days the company can operate on defensive assets alone.
Faeth Therapeutics, Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how Faeth Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check Faeth Therapeutics, Inc. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Faeth Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Faeth Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Aoyang Technology Ltd
SHE:002172
|
China | CN¥1.61 Billion |
|
Nanjing Doron Technology Corp
SHG:603528
|
China | CN¥369.28 Million |
|
Yanpai Filtration Technology Co.Ltd.
SHE:301081
|
China | CN¥1.34 Billion |
|
Hemnet Group AB
ST:HEM
|
Sweden | Skr1.14 Billion |
|
Bumi Serpong Damai Tbk
JK:BSDE
|
Indonesia | Rp25.91 Trillion |
|
SHENWAN HONGYUAN GR.H YC1
F:2X2A
|
Germany | €620.89 Billion |
|
Shore Bancshares Inc
NASDAQ:SHBI
|
USA | $5.67 Billion |
|
Qian Jiang Water Resources Development Co Ltd
SHG:600283
|
China | CN¥5.65 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Faeth Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Faeth Therapeutics, Inc. assets under control.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Faeth Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Faeth Therapeutics, Inc. (2018–2025)
The table below shows the annual total liabilities of Faeth Therapeutics, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.31 Million | -38.21% |
| 2024-12-31 | $6.97 Million | -26.42% |
| 2023-12-31 | $9.48 Million | -36.67% |
| 2022-12-31 | $14.97 Million | +123.00% |
| 2021-12-31 | $6.71 Million | +21.26% |
| 2020-12-31 | $5.54 Million | -92.08% |
| 2019-12-31 | $69.88 Million | +26.29% |
| 2018-12-31 | $55.33 Million | -- |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune chec… Read more